Brief: Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 In Phase 2b/3 COVID Study
12/05/2021 12:21
May 12 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS ANNOUNCES IFENPRODIL REDUCED
INTERLEUKIN 6 IN PHASE 2B/3 COVID STUDY
Source text for Eikon: ID:nGNX8c94hs
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement